Sigaud, R., Rösch, L., Gatzweiler, C., Benzel, J., von Soosten, L., Peterziel, H., Selt, F., Najafi, S., Ayhan, S., Gerloff, X., Hofmann, N., Büdenbender, I., Schmitt, L., Foerster, K. I., Burhenne, J., Haefeli, W. E., Korshunov, A., Sahm, F., van Tilburg, C. M., Jones, D. T. W., Pfister, S. M., Knoerzer, D., Kreider, B. L., Sauter, M., Pajtler, K. W., Zuckermann, M., Oehme, I., Witt, O., & Milde, T. (2023). the first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro-oncology, 25(3), 566–579. http://access.bl.uk/ark:/81055/vdc_100180188239.0x000013